Nuwellis, Inc. - Common Stock (NUWE)

The FDA and Nuwellis warn of potential risks linked to AquaFlexFlow UF 500 Plus blood circuits. A recall addresses issues like therapy termination and patient injury risks.

NUWE stock results show that Nuwellis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting.

Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Monday morning!